Owner Scorecard


← All companies ← CPRT Manual CPS → ← CPHI Pharmaceuticals CRMD →

CPRX, Catalyst Pharmaceuticals Inc.

Pharmaceuticals consumer brand

We currently sell three commercial stage drug products, FIRDAPSE, AGAMREE, and FYCOMPA.

Our current plans and objectives are based on assumptions relating to the continued sale of FIRDAPSE , AGAMREE and FYCOMPA and on our plans to seek to acquire or in-license additional drug products.

We are also currently seeking to further expand our product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Latest annual: FY2025 10-K
CPRX · Catalyst Pharmaceuticals Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$589M
+19.8% YoY · 38% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $597M 5-yr avg $367M
Gross margin 86% 5-yr avg 85%
Operating margin 44.8% 5-yr avg 38.0%
ROIC 78% 5-yr avg 72%
Owner-earnings margin 35% 5-yr avg 43%
Free cash flow margin 35% 5-yr avg 43%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is FIRDAPSE (61%), AGAMREE (20%) and FYCOMPA (19%).
What moves the needle
Gross margin has run about 86% and operating margin about 35% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −7059% to 48% — on a steadier 86% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has run high across the record (median 48%, above 15% in 5 of 8 years), though buybacks and expensed R&D and brands shrink the capital base, so the figure overstates the underlying economics. The steadier read is owner earnings: roughly 37% of revenue reaches owners as cash, consistently. Whether these returns reflect real pricing power or an accounting artifact is the judgment the 10-K is for.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

FIRDAPSE is 61% of revenue, with AGAMREE the other meaningful line at 20%.

Revenue by product line, FY2025
  • FIRDAPSE61%$358M
  • AGAMREE20%$117M
  • FYCOMPA19%$113M
  • License And Other Revenue0%$182K

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMMar 2026
Income statement
$0$0$500K$102M$119M$141M$214M$398M$492M$589M$597MRevenueRevenue
86%86%84%84%87%86%85%86%Gross marginGross mgn
n/m36%37%35%27%34%36%33%33%SG&A / revenueSG&A/rev
n/m18%14%12%9%23%3%2%2%R&D / revenueR&D/rev
($19M)($19M)($35M)$32M$41M$52M$102M$87M$195M$258M$268MOperating incomeOp. inc.
n/m31.1%34.7%37.2%47.5%21.8%39.7%43.8%44.8%Operating marginOp. mgn
($18M)($18M)($34M)$32M$75M$39M$83M$71M$164M$214M$221MNet incomeNet inc.
5%25%21%24%24%24%25%Effective tax rateTax rate
Cash flow & returns
($18M)($14M)($26M)$35M$45M$60M$116M$144M$240M$209M$208MOperating cash flowOp. cash
$43K$46K$38K$55K$92K$192K$141K$316K$397K$375K$330KDepreciationDeprec.
($2M)$2M$4M($1M)($36M)$15M$25M$58M$53M($31M)($39M)Working capital & otherWC & other
$96K$92K$19K$11K$1M$29K$231K$556K$58K$85KCapexCapex
18.4%0.0%0.0%0.7%0.0%0.1%0.1%0.0%0.0%Capex / revenueCapex/rev
($18M)($26M)$35M$45M$60M$116M$143M$239M$209M$208MOwner earningsOwner earn.
n/m33.8%37.8%42.7%54.2%36.0%48.7%35.4%34.9%Owner earnings marginOE mgn
($18M)($26M)$35M$45M$59M$116M$143M$239M$209M$208MFree cash flowFCF
n/m33.8%37.8%42.1%54.2%36.0%48.7%35.4%34.9%Free cash flow marginFCF mgn
$12M$7M$0$0$25MBuybacksBuybacks
-60%-63%-81%105%111%26%70%80%78%ROICROIC
-46%-23%-67%36%44%19%28%18%23%22%22%Return on equityROE
−46%−23%−67%36%44%19%28%18%23%22%22%Retained to equityRetained/eq
Balance sheet
$40M$84M$53M$95M$140M$191M$298M$138M$518M$709M$756MCash & investmentsCash+inv
$11M$6M$7M$10M$54M$65M$126M$131MReceivablesReceiv.
$0$56K$2M$5M$8M$7M$16M$20M$37M$35MInventoryInvent.
$933K$2M$2M$4M$4M$3M$4M$15M$17M$11M$7MAccounts payablePayables
($2M)($2M)$8M$6M$12M$13M$54M$68M$152M$159MOperating working capitalOper. WC
$41M$85M$55M$111M$159M$210M$321M$219M$624M$894M$940MCurrent assetsCur. assets
$2M$4M$10M$24M$23M$27M$58M$76M$121M$147M$132MCurrent liabilitiesCur. liab.
19.8×20.0×5.8×4.6×7.0×7.8×5.6×2.9×5.2×6.1×7.1×Current ratioCurr. ratio
$42M$85M$60M$112M$192M$238M$376M$470M$851M$1.1B$1.1BTotal assetsAssets
($40M)($84M)($53M)($95M)($140M)($191M)($298M)($138M)($518M)($709M)($756M)Net debt / (cash)Net debt
$39M$81M$51M$88M$170M$207M$300M$388M$728M$954M$1.0BShareholders’ equityEquity
710.1%3.7%5.3%4.3%3.7%3.6%4.5%4.2%4.2%Stock comp / revenueSBC/rev
Per share
82.9M85.8M103M106M106M108M111M114M125M127M127MShares out (diluted)Shares
$0.00$0.00$0.00$0.96$1.12$1.31$1.92$3.50$3.94$4.63$4.70Revenue / shareRev/sh
$-0.22$-0.21$-0.33$0.30$0.71$0.37$0.75$0.63$1.31$1.68$1.74EPS (diluted)EPS
$-0.22$-0.26$0.33$0.42$0.56$1.04$1.26$1.92$1.64$1.64Owner earnings / shareOE/sh
$-0.22$-0.26$0.33$0.42$0.55$1.04$1.26$1.91$1.64$1.64Free cash flow / shareFCF/sh
$0.00$0.00$0.00$0.00$0.01$0.00$0.00$0.00$0.00$0.00Cap. spending / shareCapex/sh
$0.47$0.94$0.49$0.83$1.60$1.92$2.70$3.41$5.82$7.50$7.98Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+32.8%/yr
Owner earnings / share+31.1%/yr
EPS+19.0%/yr
Capital spending / share−9.9%/yr+34.5%/yr
Book value / share+35.9%/yr+36.3%/yr

The record, charted

FY2016–2025

Each measure over its full record; the current point and the worst year marked.

Share count
127Mpeak FY2025
ROIC
80%low FY2018
Gross margin
85%low FY2022

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

$209Mowner earningsvs.$214Mnet incomelow FY2018

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2019FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported $214M of profit but $209M of owner earnings: $6M less than the profit line, taken out by capital spending and the timing of cash.

Reported net income$214M
Owner earnings$209M · 35% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$214M$164M$71M$83M$39M
Depreciation & amortizationnon-cash charge added back+$375K+$397K+$316K+$141K+$192K
Stock-based compensationreal costnon-cash, but a real cost+$25M+$22M+$14M+$8M+$6M
Working capital & othertiming of cash in and out, other non-cash items−$31M+$53M+$58M+$25M+$15M
Cash from operations$209M$240M$144M$116M$60M
Maintenance capital expenditurethe spending needed just to hold position and volume−$58K−$397K−$231K−$29K−$192K
Owner earnings$209M$239M$143M$116M$60M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$159K−$829K
Free cash flow$209M$239M$143M$116M$59M
Owner-earnings marginowner earnings ÷ revenue35%49%36%54%43%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $25M), owner earnings is nearer $184M.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash, debt-free
    Cash $709M − debt $0
    What this means

    Cash and short-term investments exceed every dollar of debt by $709M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 78 + DIO 155 − DPO 47 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not enough data
    Industry peers: median -77%
    What this means

    The filing data didn't include the inputs for this check.

  • High through the cycle
    8-yr median margin, range -5237%–54%; latest $209M = operating cash $209M − maintenance capex $58K
    Industry peers: median -44%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 35% of revenue this year, a 36% median across 8 years. Treating stock comp as the real expense it is (less $25M of SBC) leaves $184M.

  • Mostly cash-backed
    Cash from ops $209M ÷ net income $214M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks $25M ÷ Owner Earnings $209M
    What this means

    Of $209M Owner Earnings, $25M (12%) went back to shareholders, $0 dividends, $25M buybacks. Net of $25M stock comp, the real buyback was about $522K. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.15×
    Harvesting
    Capex $58K ÷ depreciation $375K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 1 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $589M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 6.08×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (10-yr record) · 3 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $1.22/share (latest year $1.75), the averaged base the calculator's gate runs on, and book value is $7.80/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 7 of 10
    What this means

    Lost money in 3 year(s), look at what happened there before trusting the average.

  • Operating margin −2331% → 35% (3-yr avg ends)

    In the filing’s words The filing ties gains to its own pricing, but names price competition too — pricing power that is real yet contested, not unopposed. The margin shows who is winning.

    What this means

    Through the cycle the operating margin widened — about −2331% early to 35% lately, median 35% — pricing power intact or improving.

  • Worst year 2018 · −7059.0% op. margin
    What this means

    Operations went underwater in 2018, understand why before trusting the good years.

  • Share count +4.9%/yr
    What this means

    The share count is rising, dilution works against you on a per-share basis.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Mar 31, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$940M
  • Cash & short-term investments$756M
  • Receivables$131M
  • Inventory$35M
  • Other current assets$19M
Current liabilities$132M
  • Accounts payable$7M
  • Other current liabilities$125M
Current ratio7.10×all current assets ÷ what's due · Graham looked for 2×
Quick ratio6.84×stricter: inventory excluded
Cash ratio5.71×strictest: cash alone against what's due
Working capital$808Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+5.6%the freshest read on whether the business is still growing
Current ratio, recent quarters5.1× → 7.1×
Deeper floors
Tangible book value$891Mequity stripped of goodwill & intangibles
Net current asset value$805MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$3M$3M of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $804M of operating cash; how management split it reads as a cash builder, a large share of cash simply built up on the balance sheet.

  • Reinvested$2M · 0%
  • Buybacks$44M · 6%
  • Retained (debt / cash)$758M · 94%
  • Returned to owners$44M

    6% of the owner earnings the business produced over the span, $0 as dividends and $44M as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span cash and short-term investments rose $715M.

  • Average price paid for buybacks

    Buybacks ran $44M over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count53.1%

    The diluted count rose from 83M to 127M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

  • Return on what it retained34%

    Of the earnings it kept rather than paid out ($583M over the span), annual owner earnings (first three years vs last three) grew $200M, so each retained $1 added about 0.34 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2022Richard J. Daly$6.9M$17.5M$116M
2023Richard J. Daly$2.1M$1.0M$143M
2024Richard J. Daly$7.8M$12.9M$239M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership<1%

    The stake all directors and executive officers hold together, per the 2025 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$25M

    The slice of the business handed to employees in shares this year, 4% of revenue, equal to 10% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Inverting the record

Invert: instead of why Catalyst Pharmaceuticals Inc. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.

1 of the 3 tests turned up something to look into; the other 2 came back clean.

  • Look hereDid the share count rise anyway?53.1%

    Diluted shares grew 53.1% over 2016–2025, even as the company spent $44M on buybacks. The repurchases were outrun by issuance — to staff, in a raise, or in a deal — and the filing says which; owners' slice still shrank. Read the buyback line beside this one, not on its own.

And these came back clean
  • Is it less profitable than it was?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
KNSAKiniksa Pharmaceuticals International, PLC$678M88%-9.3%-6%5%
RAREUltragenyx$673M100%-154.9%-92%-113%
AXSMAxsome Therapeutics Inc.$638M99%-79.2%-44%
TGTXTG Therapeutics Inc.$616M88%-29896.1%-572%-23443%
OPKOPKO Health Inc.$607M34%-18.8%-8%-13%
INSMInsmed Incorporated$606M77%-202.3%-138%-182%
CPRXCatalyst Pharmaceuticals Inc.$589M86%35.9%48%37%
MIRMMirum Pharmaceuticals Inc.$521M-58.6%-61%-38%
Group median88%-68.9%-61%-41%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Catalyst Pharmaceuticals Inc. has delivered.

$

Through the cycle, Catalyst Pharmaceuticals Inc. earns about $223M on its 37.8% median owner-earnings margin. This year’s 35.4% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+26%/yr
Owner-earnings growth · since FY2019+35%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $208M on 122M shares outstanding, per the 10-Q cover, as of 2026-05-07; net cash $756M. The if-converted diluted count is 127M, 4% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($85K) runs well above depreciation ($330K), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $208M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Catalyst Pharmaceuticals Inc. (CPRX), the owner's record," https://ownerscorecard.com/c/CPRX, data as of 2026-07-09.

Manual order: ← CPRT its page in the Manual CPS →

Industry order: ← CPHI the Pharmaceuticals chapter CRMD →